Here, we focus on one such targeted agent, the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica), and implications for its use in the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The gene discussed is BTK; the disease is mantle cell lymphoma.